Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 359 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Zyban Clear all

Conditions: Tobacco Use Disorder, Smoking
Interventions: Pharmacist-delivered group program for smoking cessation, Brief standard care session for smoking cessation delivered over the telephone; Other
Lead sponsor: University of Montana; Other
Eligibility: 21 Years and older
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Missoula, Montana

Conditions: Cigarette Smoking
Interventions: Nicotine replacement therapy - transdermal nicotine patch, Tailored behavioral intervention, Tobacco quit line referral, Nicotine replacement therapy - nicotine gum, Nicotine replacement therapy - nicotine lozenge, Bupropion Sustained Release, Varenicline, Combination pharmacotherapy - transdermal nicotine patch + nicotine gum, Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge, Combination pharmacotherapy - transdermal nicotine patch + bupropion, Alcohol use risk reduction, Behavioral activation for the treatment of depression, Behavioral management of post-cessation weight gain; Drug · Behavioral
Lead sponsor: Iowa City Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 99 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Crohn Disease
Interventions: Wellbutrin (bupropion); Drug
Lead sponsor: Altschuler, Eric, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Cocaine Dependence, Depressive Disorder, Major
Interventions: Bupropion; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Subjects
Interventions: rifampin 600 mg, itraconazole 200 mg, midazolam 2 mg with bupropion 75 mg, E2006; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Smoking Cessation
Interventions: Nicotine patch, Varenicline Tartrate, Bupropion; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 392 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Major Depressive Disorder, Dysthymia
Interventions: escitalopram, bupropion, imipramine; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Smoking
Interventions: Bupropion, Mecamylamine, Nicotine Patch; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 20 Years to 40 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Smoking Cessation
Interventions: Bupropion, Zonisamide, Placebo bupropion, Placebo zonisamide, E-cigarette; Drug · Other
Lead sponsor: Rose Research Center, LLC; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Charlotte, North Carolina • Raleigh, North Carolina

Conditions: Depressive Illness
Interventions: bupropion, citalopram; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 66 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Smoking Cessation
Interventions: Aggressive Therapy; Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Staten Island, New York

Conditions: Bipolar Disorder, Depressive Disorder
Interventions: buproprion (Wellbutrin), sertraline (Zoloft), venlafaxine (Effexor); Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Danicopan, Warfarin, Bupropion, Ethinyl Estradiol/Norethindrone; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder, Treatment Resistant Depression
Interventions: Aripiprazole Augmentation, Bupropion Augmentation; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: St Louis, Missouri • Pittsburgh, Pennsylvania

Conditions: Smoking Cessation
Interventions: Zonisamide, Bupropion, Halo G6 e-cigarette; Drug · Other
Lead sponsor: Rose Research Center, LLC; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Charlotte, North Carolina • Raleigh, North Carolina

Conditions: Smoking Cessation, Alcohol-Related Disorders
Interventions: Bupropion, placebo; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Bedford, Massachusetts

Conditions: Healthy
Interventions: Bupropion 150 mg Extended-Released Tablet, single dose, Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Smoking Cessation, Cancer, Treatment-Related
Interventions: Varenicline, Bupropion, Long-acting nicotine replacement therapy, Low-intensity counseling, High-intensity counseling, No nicotine replacement therapy, Nicotine Replacement Products; Drug · Behavioral · Other
Lead sponsor: Joseph Valentino, MD; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: Bowling Green, Kentucky • Lexington, Kentucky • Owensboro, Kentucky

Conditions: Tobacco Use Disorder
Interventions: Nicotine polacrilex, Bupropion; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years and older
Enrollment: 403 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Adolescent Methamphetamine Abuse
Interventions: Bupropion SR 150mg tabs, Placebo tablets; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 14 Years to 21 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Kidney Diseases, Major Depressive Disorder, End Stage Kidney Disease (ESRD)
Interventions: Bupropion, Behavioral activation therapy, Placebo, Clinical Management; Drug · Behavioral · Other
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 4
States / cities: Stony Brook, New York • Dallas, Texas • Seattle, Washington

Conditions: Major Depressive Disorder
Interventions: Cariprazine, Antidepressant Therapy (ADT); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 88
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 74 more

Conditions: Schizophrenia, Bipolar Disorder, Depression, Psychotic Disorders
Interventions: aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Psychoeducational multifamily group treatment, Supported employment and education; Drug · Behavioral
Lead sponsor: MaineHealth; Other
Eligibility: 12 Years to 25 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 6
States / cities: Sacramento, California • Portland, Maine • Ann Arbor, Michigan + 3 more

Conditions: Cocaine-Related Disorders
Interventions: Bupropion; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 1998
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Randomized Trial Assessing the Effectiveness of a Pharmacist-Delivered Program for Smoking Cessation

Tailored Tobacco Quitline for Rural Veterans

A Trial of Wellbutrin for Crohn's Disease

Integrated Treatment for Cocaine and Mood Disorders - 1

A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion

Individualizing Pharmacotherapy for African American Smokers

Dichotic Listening as a Predictor of Medication Response in Depression

Combinations of Pharmacologic Smoking Cessation Treatments

The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette

Add-on to Cognitive, Event-Related Potentials (ERP) and Electroencephalogram (EEG) Asymmetry in Affective Disorders

Comparison of Conservative and Aggressive Smoking Cessation Treatment Strategies in a Vascular Surgery Office Practice

Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression

A Drug Interaction Study of Danicopan

The BAARD Study : Evaluating a Computerized Approach to Treatment Selection in Older Adults With Treatment Resistant Depression.

Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes

Effectiveness of Bupropion for Smokers Recovering From Alcohol Dependence

A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions

Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment

Maintaining Nonsmoking: Older Smokers - 1

Pilot Trial of Bupropion Versus Placebo for Methamphetamine Abuse in Adolescents

Combination of Novel Therapies for CKD Comorbid Depression

Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder

Early Detection and Intervention for the Prevention of Psychosis

Cocaine Abuse and Attention Deficit Disorder - 3